Attempts to improve the formulations of topical products are continuing processes (ie, to increase cosmetic performance, enhance effects, and protect ingredients from degradation). The development of micro- and nanovesicular systems has led to the marketing of topical drugs and cosmetics that use these technologies. Several articles have reported improved clinical efficacy by the encapsulation of pharmaceuticals in vesicular systems, and the numbers of publications and patents are rising. Some vesicular systems may deliver the drug deeper in the skin as compared to conventional vehicles, or even make transdermal delivery more efficient for a number of drugs. Vesicular systems may also allow a more precise drug delivery to the site of action (ie, the hair follicles) and thereby minimize the applied drug concentration, reducing potential side effects. On the other hand, this may increase the risk of other side effects. Few case reports have suggested that microvesicle formulations may affect the allergenicity of topical products. This article gives an overview of the current knowledge about the topical use of microvesicular systems and the dermatoallergologic aspects.
Get full access to this article
View all access options for this article.
References
1.
SimonJA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause, 2006; 13: 222-31, doi:10.1097/01.gme.0000174096.56652.4f.
2.
LakshmiP, DeviG, BhaskaranS, SacchidanandS. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol, 2007; 73:157-61, doi:10.4103/0378-6323.32709.
3.
HorwitzE, PisantyS, CzerninskiR, et al.A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1999; 87:700-5, doi:10.1016/S1079-2104(99)70164-2.
4.
GodinB, TouitouE, RubinsteinE, et al.A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study. J Antimicrob Chemother, 2005; 55: 989-94, doi:10.1093/jac/dki125.
5.
de LeeuwJ, de VijlderHC, BjerringP, NeumannHA. Liposomes in dermatology today. J Eur Acad Dermatol Venereol, 2009; 23:505-16, doi:10.1111/j.1468-3083.2009.03100.x.
6.
de LeeuwJ, van der BeekN, BjerringP, Martino NeumannHA. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol, 2010; 24:460-9. [Epub 2009 Sep 30], doi:10.1111/j.1468-3083.2009.03447.x.
7.
NohynekGJ, LademannJ, RibaudC, RobertsMS. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol, 2007; 37:251-77, doi:10.1080/10408440601177780.
8.
NohynekGJ, AntignacE, ReT, ToutainH. Safety assessment of personal care products/cosmetics and their ingredients. Toxicol Appl Pharmacol, 2010; 243:239-59, doi:10.1016/j.taap.2009.12.001.
9.
SchmidM-H, KortingHC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev, 1996; 18: 335-42, doi:10.1016/0169-409X(95)00019-4.
10.
CevcG, BlumeG. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta, 2004; 1663:61-73, doi:10.1016/j.bbamem.2004.01.006.
11.
El MaghrabyGM, BarryBW, WilliamsAC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci, 2008; 34: 203-22, doi:10.1016/j.ejps.2008.05.002.
12.
BensonHA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv, 2006; 3:727-37, doi:10.1517/17425247.3.6.727.
13.
CevcG. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst, 1996; 13:257-388.
14.
GodinB, TouitouE. Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst, 2003; 20:63-102, doi:10.1615/CritRevTherDrugCarrierSyst.v20.i1.20.
15.
WissingSA, MullerRH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm, 2003; 254:65-8, doi:10.1016/ S0378-5173(02)00684-1.
16.
WissingSA, MullerRH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity—in vivo study. Eur J Pharm Biopharm, 2003; 56:67-72, doi:10.1016/S0939-6411(03)00040-7.
17.
PardeikeJ, HommossA, MüllerRH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm, 2009; 366:170-84, doi:10.1016/j.ijpharm.2008.10.003.
18.
KotylaT, KuoF, MoolchandaniV, et al.Increased bioavailability of a transdermal application of a nano-sized emulsion preparation. Int J Pharm, 2008; 347:144-8, doi:10.1016/j.ijpharm.2007.06.045.
19.
IzquierdoP, WiechersJW, EscribanoE, et al.A study on the influence of emulsion droplet size on the skin penetration of tetracaine. Skin Pharmacol Physiol, 2007; 20:263-70, doi:10.1159/ 000106076.
20.
SinhaVR, BansalK, KaushikR, et al.Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm, 2004; 278: 1-23, doi:10.1016/j.ijpharm.2004.01.044.
21.
ClemmensenA, ThormannJ, AndersenKE. Allergic contact dermatitis from retinyl palmitate in polycaprolactone. Contact Dermatitis, 2007; 56:288-9, doi:10.1111/j.1600-0536.2006.00988.x.
22.
Alvarez-RomanR, NaikA, KaliaYN, et al.Skin penetration and distribution of polymeric nanoparticles. J Control Release, 2004; 99: 53-62, doi:10.1016/j.jconrel.2004.06.015.
23.
Alvarez-RomanR, NaikA, KaliaYN, et al.Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res, 2004; 21: 1818-25, doi:10.1023/B:PHAM.0000045235.86197.ef.
24.
SheihetL, ChandraP, BathejaP, et al.Tyrosine-derived nanospheres for enhanced topical skin penetration. Int J Pharm, 2008; 350:312-9, doi:10.1016/j.ijpharm.2007.08.022.
25.
MarstonS. Propyl gallate on liposomes. Contact Dermatitis, 1992; 27:74-6, doi:10.1111/j.1600-0536.1992.tb05213.x.
26.
MadsenJT, VogelS, KarlbergA, et al.Ethosome formulations of known contact allergens can increase the sensitizing capacity. Acta Derm Venereol, 2010; 90:374-8, doi:10.2340/00015555-0874.
27.
MadsenJT, VogelS, KarlbergA, et al.Ethosome formulation of contact allergens may enhance patch test reactions in patients. Contact Dermatitis, 2010. [Submitted]
28.
TanglertsampanC, MaibachHI. The role of vehicles in diagnostic patch testing. A reappraisal. Contact Dermatitis, 1993; 29:169-74, doi:10.1111/j.1600-0536.1993.tb03531.x.
29.
BasketterDA, GerberickGF, KimberI. Skin sensitisation, vehicle effects and the local lymph node assay. Food Chem Toxicol, 2001; 39: 621-7, doi:10.1016/S0278-6915(00)00169-1.
30.
VermaDD, VermaS, BlumeG, FahrA. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm, 2003; 258:141-51, doi:10.1016/S0378-5173(03)00183-2.
